Back to Directory
Efruxifermin
Metabolic & Weight ManagementFc-FGF-21 fusion protein for NASH showing dramatic liver fat reduction.
Key Benefits
- ✓Dramatic liver fat reduction (50-70%)
- ✓Improves fibrosis
- ✓Weight loss
- ✓Improves metabolic parameters
- ✓Potential NASH treatment
Dosing Information
Dosage Range
Under investigation
Frequency
Weekly or monthly
Typical Duration
Clinical trials ongoing
Detailed Protocol
Under clinical investigation. Administered via subcutaneous injection weekly or monthly in trials. Phase 3 trials ongoing.
About Efruxifermin
Efruxifermin is an Fc-linked FGF-21 analog being developed for NASH. Phase 2 trials showed remarkable reductions in liver fat (up to 70%) and improvements in fibrosis. One of the most promising NASH drug candidates.
Research Notes
Phase 2 BALANCED trial showed up to 71% liver fat reduction. Phase 3 SYMMETRY trial ongoing. Leading NASH drug candidate with potential approval in coming years.
Potential Side Effects
- •Diarrhea
- •Nausea
- •Generally manageable
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.